Merus BV (MRUS)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

YALELAAN 62 3584 CM UTRECHT, NETHERLANDS 3584 CM

Merus B.V. operates as a clinical-stage immuno-oncology company. The Company focuses on developing bispecific antibody therapeutics. Merus develops and manufactures therapeutics to treat and cure cancer patients.

Data as of 2021-05-08 11:46:46 -0400
Market Cap778.879 Million Shares Outstanding38.35 Million Avg 30-day Volume75.438 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-8.92 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.48165 52-week High/Low31.27 / 10.18 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from MRUS instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 1 (0.06%) 1 (0.06%) 0.0%
Funds Holding: 44 42 4.76% 23 (1.38%) 22 (1.37%) 4.55%
13F shares: 21.346 Million 18.197 Million 17.3% 14.819 Million 13.367 Million 10.86%
% Ownership 73.3826 62.5584 17.3% 50.9433 45.9516 10.86%
New Positions: 8 4 100.0% 5 2 150.0%
Increased Positions 14 11 27.27% 9 6 50.0%
Closed Positions 6 6 0.0% 4 4 0.0%
Reduced Positions 10 15 -33.33% 5 6 -16.67%
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding MRUS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MRUS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

629.5 Thousand total shares from 8 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GEUIJEN CECILE A W SVP & CHIEF SCIENTIFIC OFFICER

  • Officer
21,000 2021-05-04 1

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF I GP LLC

BIOTECHNOLOGY VALUE FUND II LP

BVF II GP LLC

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF GP HOLDINGS LLC

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
7,157,552 2021-03-30 3

LUNDBERG SVEN ANTE PRESIDENT, CEO & PFO

  • Officer
  • Director
37,495 2021-03-25 4

LIU HUI EVP, CBO & HEAD OF MERUS US

  • Officer
0 2021-02-16 9

DE KRUIF JOHN SVP & CHIEF TECHNOLOGY OFFICER

  • Officer
0 2021-02-16 9

SILVERMAN PETER B. EVP, GC AND HEAD OF UTRECHT

  • Officer
0 2021-02-16 1

SHUMAN HARRY VP CONTROLLER, PAO

  • Officer
0 2021-02-16 1

BAKKER LEX SVP, CHIEF DEVELOPMENT OFFICER

  • Officer
0 2021-02-16 9

JOE ANDREW SVP, CMO

  • Officer
0 2021-02-16 3

INCYTE CORP

  • 10% Owner
3,550,000 2021-01-25 1

THROSBY MARK EVP & CHIEF SCIENTIFIC OFFICER

  • Officer
45,515 2020-07-07 4

PERRY GREGORY D

  • Director
0 2020-06-30 1

KANAVY LEN

  • Director
0 2020-06-30 1

SANDOR VICTOR

  • Director
0 2020-06-30 1

MEHRA ANAND

  • Director
0 2020-06-30 1

IWICKI MARK T

  • Director
0 2020-06-30 1

PUCCI PAOLO

  • Director
0 2020-06-30 2

BVF GP HOLDINGS LLC

BVF I GP LLC

BVF II GP LLC

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
3,190,994 2020-06-01 1

SIRULNIK ANDRES EVP & CHIEF MEDICAL OFFICER

  • Officer
0 2020-02-14 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
244,303 2020-01-16 2

GREIG RUSSELL

  • Director
0 2020-01-01 0

DE KONING JOHN

  • Director
0 2020-01-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

GEUIJEN CECILE A W - Officer SVP & CHIEF SCIENTIFIC OFFICER

2021-05-06 19:00:27 -0400 2021-05-04 A 21,000 a 21,000 direct

BVF PARTNERS L P/IL - > 10% Owner

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-04-01 17:18:23 -0400 2021-03-30 P 26,894 $19.75 a 462,015 direct -2.1693 -2.8924 0.0 1 -5.2318 3

BVF PARTNERS L P/IL - > 10% Owner

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-04-01 17:18:23 -0400 2021-03-30 P 108,106 $19.75 a 2,892,385 direct -2.1693 -2.8924 0.0 1 -5.2318 3

BVF PARTNERS L P/IL - > 10% Owner

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-04-01 17:18:23 -0400 2021-03-30 P 165,000 $19.75 a 3,803,152 direct -2.1693 -2.8924 0.0 1 -5.2318 3

LUNDBERG SVEN ANTE - Director - Officer PRESIDENT, CEO & PFO

2021-03-29 19:18:26 -0400 2021-03-25 G 74,000 d 0 direct 3.2625 10.1335 16.2135 4 0.0 1

BVF PARTNERS L P/IL - > 10% Owner

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-03-24 17:15:22 -0400 2021-03-22 P 7,744 $22.75 a 435,121 direct -0.3817 3.0057 -3.1011 13.3111 20 -6.9656 3

BVF PARTNERS L P/IL - > 10% Owner

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-03-24 17:15:22 -0400 2021-03-22 P 71,756 $22.75 a 3,638,152 direct -0.3817 3.0057 -3.1011 13.3111 20 -6.9656 3

BVF PARTNERS L P/IL - > 10% Owner

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-03-18 18:07:19 -0400 2021-03-16 P 53,061 $23.00 a 3,566,396 direct 0.9586 -9.0196 -0.7407 3.4858 24 -15.0327 7

BVF PARTNERS L P/IL - > 10% Owner

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-03-18 18:07:19 -0400 2021-03-16 P 1,171 $23.00 a 427,377 direct 0.9586 -9.0196 -0.7407 3.4858 24 -15.0327 7

BVF PARTNERS L P/IL - > 10% Owner

BIOTECHNOLOGY VALUE FUND L P SEE EXPLANATION OF RESPONSES

BVF I GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE FUND II LP SEE EXPLANATION OF RESPONSES

BVF II GP LLC SEE EXPLANATION OF RESPONSES

BIOTECHNOLOGY VALUE TRADING FUND OS LP SEE EXPLANATION OF RESPONSES

BVF PARTNERS OS LTD. SEE EXPLANATION OF RESPONSES

BVF GP HOLDINGS LLC - > 10% Owner

BVF INC/IL - > 10% Owner

LAMPERT MARK N - > 10% Owner

2021-03-18 18:07:19 -0400 2021-03-16 P 195,768 $23.00 a 2,784,279 direct 0.9586 -9.0196 -0.7407 3.4858 24 -15.0327 7

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
MERUS NV MRUS 2021-05-10 22:15:04 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 21:45:02 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 21:15:02 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 20:45:03 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 20:15:03 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 19:45:03 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 19:15:03 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 18:45:03 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 18:15:03 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 17:45:02 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 17:15:03 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 16:45:03 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 16:15:03 UTC -0.4301 0.4801 200000
MERUS NV MRUS 2021-05-10 15:45:03 UTC -0.4301 0.4801 75000
MERUS NV MRUS 2021-05-10 15:15:03 UTC -0.4301 0.4801 75000
MERUS NV MRUS 2021-05-10 14:45:04 UTC -0.3192 0.3692 75000
MERUS NV MRUS 2021-05-10 14:15:04 UTC -0.3192 0.3692 75000
MERUS NV MRUS 2021-05-10 13:45:04 UTC -0.3192 0.3692 75000
MERUS NV MRUS 2021-05-10 13:15:03 UTC -0.3192 0.3692 75000
MERUS NV MRUS 2021-05-10 12:45:02 UTC -0.3192 0.3692 65000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments